131747-53-0

Basic information

• Product Name: (6-Trifluoromethyl-pyridin-2-yl)-methanol
• Synonyms: (6-Trifluoromethyl-pyridin-2-yl)-methanol;6-(Trifluoromethyl)-2-pyridinemethanol;(6-(Trifluoromethyl)pyridine-2-yl)methanol
• CAS NO: 131747-53-0
• Molecular Formula: C₇H₆F₃NO
• Molecular Weight: 177.13
• Mol File: 131747-53-0.mol

Chemical Properties

• Boiling Point: 191.1 °C at 760 mmHg
• Flash Point: 69.4 °C
• Appearance: /
• Density: 1.362 g/cm³
• Refractive Index: 1.462
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.99±0.10(Predicted)
• CAS DataBase Reference: (6-Trifluoromethyl-pyridin-2-yl)-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (6-Trifluoromethyl-pyridin-2-yl)-methanol(131747-53-0)
• EPA Substance Registry System: (6-Trifluoromethyl-pyridin-2-yl)-methanol(131747-53-0)

Safety Data

• Hazardous Substances Data: 131747-53-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(6-Trifluoromethyl-pyridin-2-yl)-methanol is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its trifluoromethyl group is known to improve the potency and metabolic stability of drug molecules, making it an essential component in the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, (6-Trifluoromethyl-pyridin-2-yl)-methanol serves as a building block for the creation of biologically active compounds used in agriculture. Its properties contribute to the development of effective pesticides and other agrochemical products designed to protect crops and enhance agricultural productivity.
The hydroxyl group present in (6-Trifluoromethyl-pyridin-2-yl)-methanol allows for further chemical modifications and reactions, making it a versatile intermediate for the synthesis of a wide range of compounds with potential applications in both medicinal and agricultural chemistry.

InChI:InChI=1/C7H6F3NO/c8-7(9,10)6-3-1-2-5(4-12)11-6/h1-3,12H,4H2

Upstream product

• 155377-05-2 6-(trifluoromethyl)pyridine-2-carboxylic acid methyl ester 
• 68-12-2 N,N-dimethyl-formamide 
• 189278-27-1 2-bromo-6-(trifluoromethyl)pyridine 
• 1620-72-0 2-methyl-6-(trifluoromethyl)pyridine 
• 5315-25-3 2-bromo-6-methylpyridine 
• 1824-81-3 2-Amino-6-methylpyridine 
• 131747-42-7 6-(trifluoromethyl)pyridine-2-carboxylic acid 
• 131747-65-4 6-(trifluoromethyl)-2-pyridinecarboxaldehyde 
• 33674-96-3 2-bromo-6-(hydroxymethyl)pyridine 

Downstream Products

• 781637-62-5 2-(bromomethyl)-6-(trifluoromethyl)pyridine 
• 849094-03-7 2-(chloromethyl)-6-(trifluoromethyl)pyridine 
• 108337-80-0 2,6-dimethyl-4-(6-trifluoromethyl-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 
• 131747-65-4 6-(trifluoromethyl)-2-pyridinecarboxaldehyde 

Relevant articles and documents

NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to arylamide derivatives having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit,of the voltage-gated calcium channel and the μ-opioid receptor, to processes of preparation of such c

Copper-mediated perfluoroalkylation of heteroaryl bromides with (phen)CuRF

The attachment of perfluoroalkyl groups onto organic compounds has been a major synthetic goal over the past several decades. Previously, our group reported phenanthroline-ligated perfluoroalkyl copper reagents, (phen)CuR F, which react with aryl iodides and aryl boronates to form the corresponding benzotrifluorides. Herein the perfluoroalkylation of a series of heteroaryl bromides with (phen)CuCF3 and (phen)CuCF 2CF3 is reported. The mild reaction conditions allow the process to tolerate many common functional groups. Perfluoroethylation with (phen)CuCF2CF3 occurs in somewhat higher yields than trifluoromethylation with (phen)CuCF3, creating a method to generate fluoroalkyl heteroarenes that are less accessible from trifluoroacetic acid derivatives.

SEROTONIN RECEPTOR MODULATORS

The biphenyic compounds of formula (I) are serotonin modulators useful in the treatment of serotonin-mediated diseases.

OXIME ETHER DERIVATIVE AND BACTERICIDE FOR AGRICULTURAL AND HORTICULTURAL USE

The present invention provides a novel oxime ether derivative represented by the following formula (I), or salt thereof, that can be industrially produced advantageously, and can function as a fungicide for agricultural and horticultural use that has reliable effects and can be used safely, and a fungicide for agricultural and horticultural use that contains at least one of these compounds as an active ingredient thereof. In addition, the present invention provides a novel ketone derivative that is a production intermediate of the oxime ether derivative.

PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS

The present invention is directed to a novel process for preparing certain cysteine protease inhibitors.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.